Physician profile
Seif Martini
NPI 1699724070
$4,456.14
in general payments reported to CMS, 2019-2025
28 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $515 · 2021: $467 · 2022: $581 · 2023: $615 · 2024: $541 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $883.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $750.25 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $622.30 | 2019-2024 | Farxiga, Andexxa, Lynparza |
| Janssen Pharmaceuticals, INC | $550.40 | 2019-2024 | Xarelto |
| Pfizer INC. | $287.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.68 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $179.81 | 2019-2022 | |
| Esperion Therapeutics, INC. | $141.01 | 2020-2023 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.90 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $79.87 | 2021-2023 | Verquvo |
| Amgen INC. | $63.12 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $60.73 | 2019-2022 | |
| Amarin Pharma, INC. | $59.20 | 2019-2020 | |
| Boston Scientific Corporation | $51.16 | 2022-2024 | Watchman Access System |
| Abbott Laboratories | $47.75 | 2023-2025 | Cardiomems |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $45.60 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Kestra Medical Technology Services, INC. | $41.16 | 2025 | Assure Wcd |
| Chiesi USA, INC. | $36.70 | 2019 | |
| Medtronic, INC. | $32.55 | 2021-2022 | |
| Avinger INC. | $24.67 | 2023 | Pantheris |
| Lexicon Pharmaceuticals, INC. | $23.74 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $21.58 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $19.81 | 2019 | |
| Scpharmaceuticals INC. | $18.95 | 2025 | |
| Glaxosmithkline, LLC. | $14.84 | 2025 | Shingrix |
| Lantheus Medical Imaging, INC. | $12.54 | 2019 | |
| Alnylam Pharmaceuticals INC. | $11.76 | 2020 | |
| Infobionic, INC | $9.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seif Martini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.